Vascular endothelial growth factor in the circulation in cancer patients may not be a relevant biomarker
about
Current and future trials of targeted therapies in cutaneous melanomaAssociation of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma.Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO).Arteriovenous malformation and thyroid metastasis from underlying renal cell carcinoma, an unusual presentation of malignancy: A case report.Serum level and immunohistochemical expression of vascular endothelial growth factor for the prediction of postoperative recurrence in renal cell carcinoma.Pharmacokinetics and pharmacodynamics of VEGF-neutralizing antibodies.Thrombocytosis as a prognostic marker in stage III and IV serous ovarian cancer.Pre-Analytical Parameters Affecting Vascular Endothelial Growth Factor Measurement in Plasma: Identifying Confounders.A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515.Neovascularization evaluated by CD105 correlates well with prognostic factors in breast cancers.VEGF levels in plasma in relation to platelet activation, glycemic control, and microvascular complications in type 1 diabetes.Pretreatment thrombocytosis as a prognostic factor in metastatic breast cancerPre-treatment platelet counts as a prognostic and predictive factor in stage II and III rectal adenocarcinoma.The role of targeted therapy and biomarkers in breast cancer treatment.Pharmacokinetics, pharmacodynamics and pre-clinical characteristics of ophthalmic drugs that bind VEGF.Thrombocytosis as a prognostic marker in gastrointestinal cancers.The significance of nonobstructive sinusoidal dilatation of the liver: Impaired portal perfusion or inflammatory reaction syndrome.Future options of anti-angiogenic cancer therapy.A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer.Prognostic value of matrix metalloproteinase-9 expression in oral squamous cell carcinoma and its association with angiogenesis.A clear cell renal cell carcinoma inhibiting the response to intravitreal antivascular endothelial growth factor therapy in wet age-related macular disease.Biomarker accuracy: exploring the truth.Effects of Intravitreal Aflibercept on Galectin-1 and Vascular Endothelial Growth Factor-A Plasma Levels in Patients with Diabetic Retinopathy.Circulating biomarkers in renal cell carcinoma: the link between microRNAs and extracellular vesicles, where are we now?Bone marrow vascular endothelial growth factor level per platelet count might be a significant predictor for the treatment outcomes of patients with diffuse large B-cell lymphomas.Correlation of vascular endothelial growth factor plasma levels and glycemic control in patients with diabetic retinopathy.Genetic variation determines VEGF-A plasma levels in cancer patientsEvaluation of methodologies to determine the effect of specific active immunotherapy on VEGF levels in phase I clinical trial patients with advanced solid tumors
P2860
Q27022355-5A9130B2-49F4-4574-95CA-8AAD846024D5Q27852713-2AD6FBBA-3921-4002-AB15-31382F596185Q33276211-DD0BC634-3AC8-4010-B0BE-9EF117C5D6FEQ33684425-F71675D2-3D61-4037-8FDA-588FE2237EF5Q33811628-01D0E71B-94D0-447A-A965-B2069984F451Q34079689-79BDC1B5-CB98-4899-BA1F-6204F371671DQ34577000-E7BA649E-47BB-4755-B408-67DAE28001C1Q35884984-996A4306-2893-473A-9ADE-E699BD85CE0CQ36163040-322BC85D-14A2-414B-8FD6-DD0692CFD0CFQ36285676-12B275E7-A0DE-451E-83C9-1FB41D6E4529Q36868343-44222B24-2F51-48F8-BB2E-D6DF0BB4AAFFQ36999374-3FDEBBAB-2140-4041-9ED0-1D552F450BC9Q37590941-58B60F53-4B47-4459-92F1-6BE713467FEDQ38018259-376541B5-FEAF-45CA-892A-16DB535B5832Q38183850-C076364D-C175-4DE7-8D5B-807ABDFC18D1Q38190956-C2F87FA2-6BA8-48E4-8667-8BE9BBE5575BQ38356626-F5A8EFD6-569D-4EC9-AA12-78F98B46FB1DQ38438425-A3F85BC6-7E5C-412D-B382-662C9AC8E20DQ38749030-1C741C86-C22E-4364-912C-37A39A483589Q39520225-8AC5BFFF-1DB6-48F0-B3F3-BB36E136651DQ42913067-861C7825-6F0C-49C7-866A-2A7B56F78116Q46174277-BBB29BDE-C45D-40BC-A1E2-98175E48D00EQ49667627-C827C2E1-F1F7-426E-97E2-B2C190C3B685Q51854381-D27F0DF7-2A1E-4B3B-96D3-E2E355EA7066Q53066540-453C663C-6D72-4581-A0B8-1364C0E4334DQ53115047-9C057A51-DE7E-40EA-B142-5E6BC0CD0E9FQ58612325-F6292F8F-B803-4D68-BE53-3658275CFDF8Q58696969-E20E2128-8F5A-4675-81B1-33998D7B4526
P2860
Vascular endothelial growth factor in the circulation in cancer patients may not be a relevant biomarker
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Vascular endothelial growth fa ...... ay not be a relevant biomarker
@ast
Vascular endothelial growth fa ...... ay not be a relevant biomarker
@en
type
label
Vascular endothelial growth fa ...... ay not be a relevant biomarker
@ast
Vascular endothelial growth fa ...... ay not be a relevant biomarker
@en
prefLabel
Vascular endothelial growth fa ...... ay not be a relevant biomarker
@ast
Vascular endothelial growth fa ...... ay not be a relevant biomarker
@en
P2093
P2860
P1433
P1476
Vascular endothelial growth fa ...... ay not be a relevant biomarker
@en
P2093
Dick J Richel
Reinier O Schlingemann
Tatjana M H Niers
P2860
P304
P356
10.1371/JOURNAL.PONE.0019873
P407
P50
P577
2011-05-26T00:00:00Z